PT - JOURNAL ARTICLE AU - YI-CHUN CHIEN AU - YING-HSIANG CHOU AU - WEI-HSUN WANG AU - JOHN CHUN-HAO CHEN AU - WEN-SHIN CHANG AU - CHIA-WEN TSAI AU - DA-TIAN BAU AU - JENG-JONG HWANG TI - Therapeutic Efficacy Evaluation of Pegylated Liposome Encapsulated With Vinorelbine Plus <sup>111</sup>In Repeated Treatments in Human Colorectal Carcinoma With Multimodalities of Molecular Imaging AID - 10.21873/cgp.20168 DP - 2020 Jan 01 TA - Cancer Genomics - Proteomics PG - 61--76 VI - 17 IP - 1 4099 - http://cgp.iiarjournals.org/content/17/1/61.short 4100 - http://cgp.iiarjournals.org/content/17/1/61.full SO - Cancer Genomics Proteomics2020 Jan 01; 17 AB - Background/Aim: In precision therapy, liposomal encapsulated chemotherapeutic drugs have been developed to treat cancers by achieving higher drug accumulation in the tumor compared to normal tissues/organs. Materials and Methods: We developed a novel chemoradiotherapeutic approach via nanoliposomes conjugated with vinorelbine (VNB) and 111In (111In-VNB-liposome) and examined their pharmacokinetics, biodistribution, maximum tolerance dose, and toxicity in a NOD/SCID mouse model. Results: Pharmacokinetic results showed that the area under the curve (AUC) of PEGylated liposomes was about 17-fold higher than that of the free radioisotope. Tumor growth inhibition by 111In-VNB-liposome was significantly higher than that of the control (p&lt;0.05). Conclusion: The tumors in NOD/SCID mice bearing HT-29/tk-luc xenografts were significantly suppressed by 111In-VNB-liposomes. The study proposed repeated treatments with a novel liposome-mediated radiochemotherapy and validation of therapeutic efficacy via imaging.